Diabetes and cardiometabolic companies can sell to patients, payers, employers, or providers – but each requires an entirely different motion. We develop the GTM strategy that identifies the right buyer and motion, positions for both, and sequences channels so you commit by design rather than by default.
The Challenge
Several viable buyers can pull the company in conflicting directions
A cardiometabolic company can plausibly sell to patients, payers, employers, or providers, and each requires a different motion, proof, and org. Chasing several at once with a small team means doing all of them badly. The core strategic decision – which buyer to lead with and in what sequence – has to be made deliberately, because getting it wrong wastes a year of runway.
Positioning designed for one buyer can push the others away
Messaging that lands with a patient can undermine credibility with a payer, and clinical positioning that convinces a provider can confuse a consumer. A single generic position serves none of them well. GTM strategy has to define positioning tuned to the chosen buyer and motion, not a lowest-common-denominator message that tries to speak to everyone.
Your ability to win depends on the motion, not only the message
A self-serve patient motion, an enterprise payer sale, and a provider-referral motion demand different teams, cycles, and economics, and a company built for one cannot execute another by force of will. Teams that pick a message before picking a motion end up with an org that cannot deliver. Choosing the motion is a foundational GTM decision, not a downstream tactic.
Pricing and packaging are determined before the buyer is selected
How you price and package for a self-paying patient is unrelated to how you structure a payer contract or an employer deal, yet pricing often gets locked in before the go-to-market motion is decided. That forces expensive rework or caps the deals you can do. Pricing and packaging have to follow the buyer and motion decision, not precede it.
How We Help
We begin with the decision every other choice rests on: which buyer should come first. We assess patient, payer, employer, and provider motions against your product, economics, and stage, then recommend a primary buyer and a sequence for the rest, grounding the [growth strategy](/services/strategy/) in an intentional choice rather than a default.
Once the buyer is selected, we choose the motion realistically. Self-serve patient, enterprise payer, and provider-referral models each require a different team, cycle, and cost structure, so we define the motion your company can genuinely execute and what building it will require. Choosing the motion ahead of the message keeps the organization and strategy aligned.
Through our [marketing](/services/marketing/) practice, we create positioning tailored to that buyer and motion – a position that builds credibility with the selected buyer rather than a generic message weakened by trying to reach everyone. Precise positioning for one buyer outperforms vague positioning for all.
We establish pricing and packaging suited to the motion – self-pay models for patients, contract models for payers and employers – so commercial terms support the strategy instead of limiting it. This avoids the costly rework caused by setting pricing before choosing the buyer.
Through our [measurement](/services/measurement/) practice, we sequence channels and establish measurement, giving the plan a defined order of operations and a way to determine whether the selected motion works before betting the company on it. GTM strategy is a testable set of decisions, not a static plan.
We do not simply deliver a market-sizing deck. We make the difficult buyer-and-motion choices, build positioning around them, and provide a sequenced plan you can execute confidently.
What we deliver
- A primary-buyer decision across patient, payer, employer, and provider motions
- An honest motion selection matched to what the org can execute
- Positioning tuned to the chosen buyer, not a diluted general message
- Pricing and packaging that follow the motion, not precede it
- A sequenced channel plan with a clear order of operations
- Measurement to validate the motion before betting the company on it
In diabetes and cardiometabolic health, the most consequential decision is not the message – it is the buyer you lead with, because patient, payer, employer, and provider motions require distinct organizations, economics, and positioning, and a company designed for one cannot force its way into winning another.
Our Methodology
Our 90-day sprint delivers a GTM strategy grounded in deliberate choices, not a market-sizing exercise. Days 1-30 address the central decision: we assess viable buyer motions against your product, economics, and stage, then recommend a primary buyer and sequence. This phase concludes with a buyer-and-motion choice the leadership team can support.
During days 31-60, we construct the strategy around that choice. We develop buyer-specific positioning, establish pricing and packaging aligned with the motion, and organize channels into a clear sequence of operations. Every component stems from the buyer decision instead of being determined separately.
Days 61-90 turn the plan into something testable and transfer it to your team. We implement measurement to show whether the selected motion is performing, identify signals that would warrant changing the sequence, and document the strategy so the team can execute confidently. Since GTM consists of bets that must be validated, the sprint provides decisions and a method for testing them rather than a static plan.
How We Work
During the first 30 days, we collaborate with your founder and leadership team on selecting the primary buyer, because committing to a motion is a leadership decision with company-wide implications. Expect candid, occasionally uncomfortable sessions that weigh each motion against your actual constraints.
Days 30-60 shape the strategy around the selected buyer – including positioning, pricing and packaging, and channel sequencing – ensuring each component flows from the decision instead of being developed independently.
Days 60-90 focus on making the plan testable and transferring it to the team. We implement measurement that validates the motion, identify signals that would alter the sequence, and document the strategy. Since GTM decisions must withstand real market conditions, many engagements extend into early execution so the plan can be refined as genuine signals emerge.
A senior strategist with experience leading GTM in health heads the team, with support from marketing and measurement specialists so positioning and validation launch alongside the strategy, not afterward.
- A deliberate primary-buyer and motion decision
- Positioning tuned to the chosen buyer
- Pricing and packaging aligned to the motion
- A sequenced channel plan with clear order of operations
- A way to validate the motion before betting the company
If your diabetes & cardiometabolic health company needs gtm strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does a diabetes or cardiometabolic GTM strategy engagement cost?
A GTM strategy engagement generally costs $20K-$45K for the 90-day sprint, based on the number of buyer motions requiring evaluation and the extent of subsequent positioning and pricing work. Pricing reflects the depth of decision-making and planning rather than a predetermined number of deliverables. Since the buyer-and-motion choice can prevent a year of misallocated runway, the investment is evaluated against the cost of making the wrong decision.
What is the most difficult part of GTM strategy in this category?
The greatest challenge is deciding which buyer to prioritize, since patient, payer, employer, and provider motions each demand different organizations, economics, and positioning. A small team pursuing multiple motions simultaneously will execute all of them poorly. We make that choice intentionally and sequence the remaining buyers, which is where much of the value lies.
How do you determine whether to sell to patients, payers, or providers?
We assess every motion against your product, unit economics, stage, and the organization's realistic ability to execute, then recommend one primary buyer and a sequence for the others. The choice considers more than market size; it also asks whether you can build the team and motion needed to win that buyer. It is an intentional commitment, not a simultaneous bet on everyone.
How does GTM strategy differ from a go-to-market execution engagement?
GTM strategy addresses the upstream choices – buyer, motion, positioning, pricing, and channel sequence – that shape what gets executed. A go-to-market execution engagement subsequently turns those decisions into launch and commercial readiness. Strategy establishes the direction and bets; execution creates the machine that runs them.
How can you tell whether the selected motion is actually working?
We implement measurement connected to the selected motion's leading indicators – qualified pipeline for a payer sale, enrollment and retention for a patient motion – and identify the signals that would warrant changing the sequence. This enables you to validate the bet with real data before the entire company commits to it. GTM is approached as a collection of testable decisions rather than a fixed plan.
What does the process of starting a GTM strategy engagement involve?
We begin by assessing viable buyer motions against your product, economics, and stage, then guide the leadership team toward a primary-buyer decision. That choice becomes the foundation for the positioning, pricing, and channel sequence developed next. If your diabetes or cardiometabolic company is pursuing multiple buyers without a defined motion, we should talk.
